FOLLOW US

In a strategic move that sent shockwaves through the biopharmaceutical industry, AbbVie Inc. announced on Monday its intention to acquire Landos Biopharma Inc. for a staggering sum of up to $212.5 million. Led by legal powerhouses Paul Weiss Rifkind Wharton & Garrison LLP and Cooley LLP, the deal marks a significant milestone in the realm of clinical-stage biopharmaceutical advancements.

AbbVie to buy Landos Biopharma for $212M : A Lucrative Deal Unveiled

Under the terms of the agreement, AbbVie pledges to shell out $20.42 in cash per Landos share upon closure, totaling approximately $137.5 million. In addition, contingent value rights of up to $11.14 per share are on offer, potentially adding a hefty $75 million to the deal if specific clinical milestones are achieved, as disclosed by AbbVie in a statement.

The market responded with fervor as Landos' stock surged a remarkable 167%, closing at an impressive $21.40 per share on Monday, following the announcement.

Trailblazing Innovations in Biopharma

Headquartered in Blacksburg, Virginia, Landos Biopharma stands at the forefront of innovation in autoimmune disease treatments. Its flagship asset, NX-13, presents a promising anti-inflammatory therapy for individuals grappling with ulcerative colitis and Crohn's disease. Currently undergoing clinical trials across the United States and Europe, NX-13 holds immense potential to revolutionize patient care in these critical areas.

Dr. Roopal Thakkar, AbbVie's Chief Medical Officer for Global Therapeutics, underscored the significance of NX-13, hailing it as a "differentiated, first-in-class, oral asset" with the power to positively impact the lives of those afflicted by ulcerative colitis and Crohn's disease.

Strategic Vision and Industry Leadership

With the transaction slated for closure in the second quarter of 2024, pending regulatory approval and fulfillment of closing conditions, AbbVie emerges as a pivotal player in steering NX-13 towards its full potential. Gregory Oakes, CEO of Landos Biopharma, expressed confidence in AbbVie's prowess, citing their expertise and leadership in therapeutic areas as instrumental in propelling NX-13 forward.

AbbVie's pursuit of transformative acquisitions has been evident in its recent endeavors. Earlier announcements included the acquisition of cancer drugmaker ImmunoGen Inc. for a staggering $10.1 billion and a deal with Cerevel Therapeutics valued at approximately $8.7 billion.

AbbVie to buy Landos Biopharma for $212M : Legal Titans Pave the Way

Behind the scenes, legal heavyweights orchestrated the intricate details of the acquisition. The Paul Weiss team, led by corporate partners Benjamin Goodchild and Krishna Veeraraghavan, spearheaded AbbVie's representation. Meanwhile, Cooley LLP, under the guidance of corporate partners Kevin Cooper and Eric Blanchard, navigated Landos Biopharma through the complexities of the deal.

As AbbVie charts its course towards bolstering its portfolio and advancing groundbreaking therapies, the acquisition of Landos Biopharma stands as a testament to its unwavering commitment to medical innovation and patient well-being.